Bioequivalence and Pharmacokinetics of Low-Dose Anagrelide 0.5 mg Capsules in Healthy Volunteers

<b>Objectives</b>: Anagrelide, an oral phosphodiesterase-3 inhibitor, is widely used to treat thrombocythemia. Evaluating the bioequivalence of low-dose formulations is essential to ensure consistent therapeutic outcomes while minimizing adverse effects, particularly cardiovascular event...

Full description

Bibliographic Details

Published in:	Biomedicines
Main Authors:	Ahmet Inal, Zafer Sezer, Onur Pinarbasli, Burcu Bulut, Martin Reinsch, Wolfgang Martin, Mumtaz M. Mazicioglu, Selma Alime Koru
Format:	Article
Language:	English
Published:	MDPI AG 2025-08-01
Subjects:	anagrelide bioequivalence pharmacokinetics LC-MS/MS healthy volunteers fasting
Online Access:	https://www.mdpi.com/2227-9059/13/8/1993